OrSense Ltd., of Nes Ziona, Israel, is another recipient of the technology innovation award from Frost & Sullivan for its non-invasive glucose monitoring system NBM-200. The system, based on proprietary “occlusion spectroscopy” technology, allows continuous measurement of blood glucose, hemoglobin, hematocrit, oximetry, and heart rates. Results from a clinical trial, reported in September, have shown that the system “accurately measures levels of glucose in a home-like setting.”
The technology in a nut shell:
OrSense’s patented technology, known as Occlusion Spectroscopy, uses a non-invasive optical measurement platform combined with a ring-shaped cuff. The pressure applied by the cuff temporarily occludes the blood flow in the finger, creating new blood dynamics which generate a strong optical signal, yielding a high signal-to-noise ratio that is wholly blood specific. Analysis of the signal provides the sensitivity necessary to measure blood glucose, hemoglobin, and other analyte concentrations.
OrSense’s primary product is a non-invasive blood glucose monitor, for both continuous and spot measurements. It allows self monitoring of blood glucose levels by people with diabetes. The first generation monitor to enter the market, the NBM-200G, is a non-invasive continuous glucose monitor, focused on patients with demanding need for glycemic control in cases such as brittle, nocturnal, and gestational diabetes. The NBM-200G was tested on over 350 subjects, exhibiting comparable accuracy to invasive solutions, while providing superior ease of use and safety. Furthermore, the NBM-200G enables the identification of glucose trends and the detection of hypo- and hyperglycemia events. In an additional clinical application, the NBM-200G may optimally answer the growing need for tight glycemic control in acute care setting.
The diabetics will be happy to know that according to the company, the device is expected to be submitted for regulatory approval (FDA?) during 2007, and to enter the market in 2008.
(hat tip: Globes [online]…)